drugset / Trial / NCT04412538

Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19

NCT04412538

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study is a randomized, double-blinded, and placebo-controlled phase Ia/IIa clinical trial of the Inactivated SARS-CoV-2 Vaccine to evaluate the safety and immunogenicity of the vaccine in healthy people aged 18\~59 Years.

Timeline

Start
2020-05-15
Primary completion
2020-08-10
Completion
2021-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject inactivated SARS-CoV-2 vaccine Vaccine 50 iu Intramuscular
Subject inactivated SARS-CoV-2 vaccine Vaccine 100 iu Intramuscular
Subject inactivated SARS-CoV-2 vaccine Vaccine 150 iu Intramuscular

Indications